Oficiálny časopis Slovenskej kardiologickej spoločnosti,
Slovenskej hypertenziologickej spoločnosti a Slovenskej asociácie srdcových arytmií

Cardiology Letters 2021, 30(3):141-147

Komentár k ESC 2020 Odporúčaniam pre diagnostiku a manažment fibrilácie predsiení

Hatala R, Svetlošák M
NÚSCH, a. s. a Lekárská fakulta Slovenskej zdravotníckej univerzity, Bratislava, Slovenská republika

Uverejnené: March 1, 2021  Zobraziť citáciu

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hatala R, Svetlošák M. Komentár k ESC 2020 Odporúčaniam pre diagnostiku a manažment fibrilácie predsiení. Cardiology Letters. 2021;30(3-4):141-147.
Stiahnuť citáciu

Referencie

  1. Staerk L, Wang B, Preis SR, et al. Lifetime risk of atrial fibrillation according to optimal, borderline, or elevated levels of risk factors: cohort study based on longitudinal data from the Framingham Heart Study. BMJ. 2018;361:k1453. doi: 10.1136/bmj.k1453. Prejsť k pôvodnému zdroju...
  2. Krijthe BP, Kunst A, Benjamin EJ, et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J. 2013;34:2746-2751. doi: 10.1093/eurheartj/eht280. Prejsť k pôvodnému zdroju...
  3. Kirchhof P, Benussi S, Kotecha D, et al. ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893-2962. doi: 10.1093/eurheartj/ehw210. Prejsť k pôvodnému zdroju...
  4. Hindricks G, Potpara T, Dagres N, et al. ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42:373-498. doi: 10.1093/eurheartj/ehaa612 Prejsť k pôvodnému zdroju...
  5. https://academic.oup.com/eurheartj/article/42/5/373/5899003
  6. van den Dries CJ, van Doorn S, Rutten FH, et al. Integrated management of atrial fibrillation in primary care: results of the ALL-IN cluster randomized trial. Eur Heart J. 2020;41:2836-2844. doi: 10.1093/eurheartj/ehaa055. Prejsť k pôvodnému zdroju...
  7. Svendsen JH, Diederichsen SZ, Højberg S, et al. Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial. Lancet. 2021:S0140-6736(21):01698-6. doi: 10.1016/S01406736(21)01698-6. Prejsť k pôvodnému zdroju...
  8. Hatala R, Hlivak P, Urban L, et al. Thromboembolic risk profile in patients with atrial fibrillation in internal and cardiologic outpatient clinics in Slovakia: Data from REgistry of AtriaL FIBrillation in real life practice (REALFIB). Cardiology Lett. 2012;21:98-110.
  9. Glikson M, Wolff R, Hindricks G, et al. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion - an update. EuroIntervention. 2020 17;15:1133-1180. doi: 10.4244/EIJY19M08_01. Prejsť k pôvodnému zdroju...
  10. Wyse DG, Waldo AL, DiMarco JP, et al. Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:18251833. doi: 10.1056/NEJMoa021328. Prejsť k pôvodnému zdroju...
  11. Crijns HJ. Rate versus rhythm control in patients with atrial fibrillation: what the trials really say. Drugs. 2005;65:1651-1667. doi: 10.2165/00003495-200565120-00004. Prejsť k pôvodnému zdroju...
  12. Kirchhof P, Camm AJ, Goette, et al. EAST-AFNET 4 Trial Investigators. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. N Engl J Med. 2020;383:1305-1316. doi: 10.1056/NEJMoa2019422. Prejsť k pôvodnému zdroju...